Cost of postoperative complications of lower anterior resection for rectal cancer: a nationwide registry study of 15,187 patients.

"Declarations Conflict of interestDr. Kumamaru received speaker fees from Pfizer Japan Inc., Chugai Pharmaceutical Co., Ltd., and Johnson & Johnson K.K., and a consultation fee from Mitsubishi Tanabe Pharma Corporation. Dr. Yamamoto received a consultation fee from Mitsubishi Tanabe Pharma, a speaker fee from Chugai Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd., and payment for a manuscript from Astellas Pharma Inc. Drs. Kumamaru, Yamamoto, Iwanaka and Miyata are affiliated with the Department of Healthcare Quality Assessment at The University of Tokyo, which is a social collaboration department supported by the National Clinical Database, Johnson & Johnson K.K., and Nipro Corporation. Dr. Kitagawa reports receiving grants from CHUGAI PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD, Yakult Honsha Co. Ltd., ASAHI KASEI PHARMA CORPORATION, Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., ONO PHARMACEUTICAL CO., LTD., TSUMURA & CO., Kyouwa Hakkou Kirin Co., Ltd., MEDICON INC., Eisai Co., Ltd., and Otsuka Pharmaceutical Factory Inc. Dr Kitagawa also discloses receiving personal fees from ONO PHARMACEUTICAL CO., LTD., and Bristol-Myers Squibb K.K., outside the submitted work. The other authors have no potential conflicts of interest to disclose. Approval of the research protocolThe study was reviewed and approved by the Institutional Review Board of the University of Tokyo Graduate School of Medicine and Faculty of Medicine (ID: 11467). Informed consentAn opt-out method was used for this observational study using preexisting medical information in the database. Participating facilities posted information about the use of clinical and administrative data for research purposes, and patients who chose not to participate were removed from the study database. Registry and the Registration No. of the study/TrialNA. Animal studiesNA. Conflict of interest Dr. Kumamaru received speaker fees from Pfizer Japan Inc., Chugai Pharmaceutical Co., Ltd., and Johnson & Johnson K.K., and a consultation fee from Mitsubishi Tanabe Pharma Corporation. Dr. Yamamoto received a consultation fee from Mitsubishi Tanabe Pharma, a speaker fee from Chugai Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd., and payment for a manuscript from Astellas Pharma Inc. Drs. Kumamaru, Yamamoto, Iwanaka and Miyata are affiliated with the Department of Healthcare Quality Assessment at The University of Tokyo, which is a social collaboration department supported by the National Clinical Database, Johnson & Johnson K.K., and Nipro Corporation. Dr. Kitagawa reports receiving grants from CHUGAI PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD, Yakult Honsha Co. Ltd., ASAHI KASEI PHARMA CORPORATION, Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., ONO PHARMACEUTICAL CO., LTD., TSUMURA & CO., Kyouwa Hakkou Kirin Co., Ltd., MEDICON INC., Eisai Co., Ltd., and Otsuka Pharmaceutical Factory Inc. Dr Kitagawa also discloses receiving personal fees from ONO PHARMACEUTICAL CO., LTD., and Bristol-Myers Squibb K.K., outside the submitted work. The other authors have no potential conflicts of interest to disclose."

"Funding This study was funded, in part, by Japan Agency for Medical Research and Development [AMED] (grant number 16lk1010004h0002), the National Clinical Database, and Johnson & Johnson K.K. Johnson & Johnson K.K. was involved in the conceptualization of the study. None of the funding organizations were involved in the design and conduct of the study, data collection, data management and analysis, interpretation of data, preparation, review or approval of the manuscript, or the decision to submit the manuscript for publication."

"Declarations: Conflict of interestDr. Kumamaru received speaker fees from Pfizer Japan Inc., Chugai Pharmaceutical Co., Ltd., and Johnson & Johnson K.K., and a consultation fee from Mitsubishi Tanabe Pharma Corporation. Dr. Yamamoto received a consultation fee from Mitsubishi Tanabe Pharma, a speaker fee from Chugai Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd., and payment for a manuscript from Astellas Pharma Inc. Drs. Kumamaru, Yamamoto, Iwanaka and Miyata are affiliated with the Department of Healthcare Quality Assessment at The University of Tokyo, which is a social collaboration department supported by the National Clinical Database, Johnson & Johnson K.K., and Nipro Corporation. Dr. Kitagawa reports receiving grants from CHUGAI PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD, Yakult Honsha Co. Ltd., ASAHI KASEI PHARMA CORPORATION, Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., ONO PHARMACEUTICAL CO., LTD., TSUMURA & CO., Kyouwa Hakkou Kirin Co., Ltd., MEDICON INC., Eisai Co., Ltd., and Otsuka Pharmaceutical Factory Inc. Dr Kitagawa also discloses receiving personal fees from ONO PHARMACEUTICAL CO., LTD., and Bristol-Myers Squibb K.K., outside the submitted work. The other authors have no potential conflicts of interest to disclose.: Approval of the research protocolThe study was reviewed and approved by the Institutional Review Board of the University of Tokyo Graduate School of Medicine and Faculty of Medicine (ID: 11467).: Informed consentAn opt-out method was used for this observational study using preexisting medical information in the database. Participating facilities posted information about the use of clinical and administrative data for research purposes, and patients who chose not to participate were removed from the study database.: Registry and the Registration No. of the study/TrialNA.: Animal studiesNA."